Thermo Fisher Scientific Inc. $TMO Shares Sold by Stevens Capital Partners

Stevens Capital Partners decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 75.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 357 shares of the medical research company’s stock after selling 1,088 shares during the quarter. Stevens Capital Partners’ holdings in Thermo Fisher Scientific were worth $241,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. ProShare Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.1% in the 3rd quarter. ProShare Advisors LLC now owns 60,294 shares of the medical research company’s stock valued at $40,701,000 after purchasing an additional 658 shares during the last quarter. Vise Technologies Inc. increased its stake in shares of Thermo Fisher Scientific by 48.1% during the third quarter. Vise Technologies Inc. now owns 13,494 shares of the medical research company’s stock worth $9,109,000 after acquiring an additional 4,382 shares during the period. Investment Partners LTD. raised its stake in shares of Thermo Fisher Scientific by 12.5% during the 3rd quarter. Investment Partners LTD. now owns 1,597 shares of the medical research company’s stock worth $1,079,000 after buying an additional 178 shares in the last quarter. Cidel Asset Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 1.9% in the 3rd quarter. Cidel Asset Management Inc. now owns 2,224 shares of the medical research company’s stock valued at $1,501,000 after buying an additional 41 shares during the period. Finally, Summit Global Investments boosted its stake in shares of Thermo Fisher Scientific by 72.3% in the third quarter. Summit Global Investments now owns 2,178 shares of the medical research company’s stock valued at $1,471,000 after buying an additional 914 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 2,831 shares of the business’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $706.45, for a total value of $1,999,959.95. Following the sale, the vice president owned 11,560 shares of the company’s stock, valued at $8,166,562. The trade was a 19.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 76,199 shares of company stock valued at $45,896,780 over the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Guggenheim began coverage on Thermo Fisher Scientific in a research report on Thursday, October 15th. They issued a “buy” rating for the company. Argus boosted their target price on shares of Thermo Fisher Scientific from $560.00 to $780.00 and gave the stock a “buy” rating in a research report on Friday. CLSA assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price target on the stock. Stifel Nicolaus increased their price target on shares of Thermo Fisher Scientific from $650.00 to $775.00 and gave the company a “buy” rating in a report on Thursday, October 22nd. Finally, BMO Capital Markets cut shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $689.10.

Thermo Fisher Scientific Stock Down 0.0%

Shares of NYSE TMO opened at $696.78 on Monday. The firm has a market cap of $257.63 billion, a P/E ratio of 36.75, a price-to-earnings-growth ratio of 2.84 and a beta of 0.84. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $711.85. The firm’s 50 day moving average price is $654.87 and its 200 day moving average price is $552.94.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same period last year, the company earned $5.79 earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.